Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
-
Randomized Controlled Trial Multicenter Study
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Interleukin 13 (IL13) is a T-helper type 2 (Th2) cytokine associated with inflammation and pathology in allergic diseases such as bronchial asthma. We have shown that treatment with lebrikizumab, an anti-IL13 monoclonal antibody, significantly improves prebronchodilator forced expiratory volume in 1 s (FEV(1)) in a subset of subjects with uncontrolled asthma. ⋯ Lebrikizumab reduced the LAR in subjects with mild asthma. Clinical trial number NCT00781443.
-
Randomized Controlled Trial
OX40L blockade and allergen-induced airway responses in subjects with mild asthma.
The OX40/OX40L interaction contributes to an optimal T cell response following allergic stimuli and plays an important role in the maintenance and reactivation of memory T effector cells. ⋯ Pharmacological activity of anti-OX40L MAb was observed by decreases in serum total IgE and airway eosinophils at 16 weeks post-dosing, but there was no effect on allergen-induced airway responses. It is possible that the treatment duration or dose of antibody was insufficient to impact the airway responses.